<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69281">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02203903</url>
  </required_header>
  <id_info>
    <org_study_id>RESOLVE</org_study_id>
    <nct_id>NCT02203903</nct_id>
  </id_info>
  <brief_title>Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies</brief_title>
  <official_title>Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catherine Bollard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Children's Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase I dose-escalation trial is designed to evaluate the safety of administering
      rapidly-generated multi-antigen-specific T lymphocytes, to HSCT recipients (group A) or
      future HSCT recipients (group B) for the treatment or relapsed or refractory hematopoietic
      malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with evidence of relapsed or persistent hematopoietic malignancies (e.g. acute
      leukemia, MDS, Hodgkins lymphoma, CML) will be eligible for this study. Patients will be
      enrolled at two time points (for differing indications) in two groups (Group A - post HSCT
      and Group B- pre HSCT). Because patients with persistent malignancy prior to transplantation
      have an extremely poor prognosis, these patients will be eligible to receive TAA-CTL before
      and/or after allogeneic hematopoietic stem cell transplantation (HSCT). Group B patients may
      receive autologous TAA-CTL following a cycle of conventional chemotherapy in an effort to
      decrease the burden of disease prior to HSCT. Additionally, patients with persistent disease
      or high risk for relapse will be eligible to receive planned infusion of TAA-CTL after HSCT
      (given the very high likelihood of relapse and poor outcome) on group A. These high
      risk/refractory patients and their donors will be enrolled prior to HSCT and TAA-CTL will be
      given any time after day 30 post HSCT

      In either population, we will utilize a rapid generation protocol for multi-antigen specific
      T lymphocytes. Peripheral blood mononuclear cells will be exposed to antigen presenting
      cells pulsed with peptides to tumor antigens (Prame, WT1, Survivin, and MAGE-A3) in a
      cytokine milieu favorable to T cell expansion/activation, inducing selective expansion of T
      cells targeted to kill tumor cells. Patients would be monitored for the development of
      toxicity. In patients with disease at the time of TAA-CTL infusion, efficacy would be
      evaluated as a secondary endpoint using standard criteria. Exploratory investigational
      analyses would include monitoring of cytokine and cellular milieu pre- and post- TAA-CTL
      infusion and in vitro characterization of the host tumor, donor lymphocyte product, and
      TAA-CTL product.

      For Group A Patients (post HSCT): T cells will be infused any time after neutrophil
      engraftment post-HSCT or day 30, whichever comes first.

      For Group B Patients (pre HSCT): T cells will be infused any time &gt;1 week after previous
      therapy for relapsed disease.

      Four different dosing schedules will be evaluated. Two to four patients will be evaluated on
      each dosing schedule (see below). This protocol is designed as a phase I dose-escalation
      study.

      Each patient will receive 1 injection per dose level, at least 14 days apart, according to
      the following dosing schedules. The expected volume of infusion will be 1 to 10 cc.

      Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107
      cells/m2 Dose Level Four: 4 x 107 cells/m2

      Patients will receive cells either because: of prior refractory disease and/or high risk for
      relapse and/or detectable disease at the time of infusion. Group A and Group B patients will
      use the dose escalation strategy described above. Ideally, patients should not receive other
      systemic antineoplastic agents for at least 6 weeks after infusion of TAA- specific T-cells
      (for purposes of evaluation), although such treatment may be added at the discretion of
      their attending physician.

      If patients with active disease have stable disease or a partial response by the
      International Working Group (IWG) criteria at their 8 week or subsequent evaluations they
      are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which
      will consist of the same cell number as their second injection. Patients will not be able to
      receive additional doses until the initial safety profile is completed at 6 weeks following
      the second infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>within 45 days of the last dose of TAA-CTL</time_frame>
    <description>Safety including acute GVHD grades III-IV within 45 days of the last dose of TAA-CTL or grades 3-5 infusion-related adverse events within 45 days of the last TAA-CTL dose or grades 4-5 non-hematological attributable adverse events within 45 days of the last TAA-CTL dose and that are not due to the pre-existing infection or the original malignancy or pre-existing co-morbidities as defined by the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 4.X.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor associated antigen lymphocytes (TAA-CTL) responses</measure>
    <time_frame>2 years</time_frame>
    <description>- To determine the number of patients who respond to tumor associated antigen lymphocytes (TAA-CTL) for the treatment for relapsed/refractory hematopoietic malignancies as defined by those who achieve CR, PR, MR, or SD following cell infusion and evaluate if this was associated with in vivo persistence of TAA-CTL.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The incidence and severity of acute and/or chronic GVHD</measure>
    <time_frame>2 years</time_frame>
    <description>To determine the incidence and severity of acute and/or chronic GVHD in patients treated with TAA-CTL and compare this to historical controls</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Relapsed/Refractory Hematopoietic Malignancies</condition>
  <arm_group>
    <arm_group_label>Tumor associated antigen lymphocytes (TAA-CTL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor associated antigen lymphocytes (TAA-CTL). Four different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule (see below). This protocol is designed as a phase I dose-escalation study.
Each patient will receive 1 injection per dose level, at least 14 days apart, according to the following dosing schedules.
Dose Level One: 5 x 106 cells/m2 Dose Level Two: 1 x 107 cells/m2 Dose Level Three: 2 x 107 cells/m2 Dose Level Four: 4 x 107 cells/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tumor associated antigen lymphocytes (TAA-CTL)</intervention_name>
    <description>TAA-CTL may be generated from donors or recipients and will be tested for specificity to 4 tumor antigens commonly found in hematological malignancies (WT1, PRAME, SURVIVIN, and MAGE-A3). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).</description>
    <arm_group_label>Tumor associated antigen lymphocytes (TAA-CTL)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Recipient procurement Inclusion criteria

          -  Patients who have undergone allo-HSCT with high risk for relapse or
             residual/recurrent disease (see below) OR patients with relapsed/refractory disease
             (&gt; 2 regimens with greater than M1 marrow or persistent HD) with anticipated
             allo-HSCT pre- and/or post-HSCT:

          -  Acute lymphoblastic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia or
             lymphoma, Chronic Myelogenous leukemia, Myelodysplastic syndrome:

          -  Evidence of active leukemia or lymphoma disease by flow cytometry, morphology, or
             cytogenetic evaluation within the marrow or extramedullary sites

          -  Hodgkins disease:

          -  Evidence of HD by morphology, PET/CT uptake in a site of previous disease in the
             absence of other etiologies

          -  Age 6 months to 30 years

          -  Karnofsky/Lansky score of &gt; 50 (see appendix B).

          -  Absolute neutrophil count &gt; 500/ ÂµL (may be supported with GCSF)

          -  Bilirubin &lt; 2.5 mg/dL, AST/ALT &lt;5x upper limit of normal, Serum creatinine &lt; 1.0 or
             2x the upper limit of normal (whichever is higher)

          -  Pulse oximetry of &gt; 90% on room air

          -  Agree to use contraceptive measures during study protocol participation (when age
             appropriate)

          -  LVEF &gt; 50% or LVSF &gt; 27% if history of TBI (may be performed within the last 6
             months)

          -  Patient or parent/guardian capable of providing informed consent

        Recipient Inclusion criteria for initial CTL administration and for subsequent infusions

          -  Steroids less than 0.5 mg/kg/day prednisone or equivalent

          -  Karnofsky/Lansky score of &gt; 50

          -  -Pulse oximetry of &gt; 90% on room air

        Exclusion Criteria:

        Recipient Procurement Exclusion Criteria

          -  Patients with uncontrolled infections

          -  Patients with HIV infection

          -  Current evidence of GVHD &gt; grade 2 or bronchiolitis obliterans syndrome, sclerotic
             GVHD, or serositis.

          -  Pregnancy or lactating (female of childbearing potential)

        Recipient Exclusion criteria for initial and subsequent CTL infusions

          -  Patients receiving ATG, or Campath or other immunosuppressive T cell monoclonal
             antibodies within 28 days of screening for enrollment.

          -  Uncontrolled infections

          -  Acute GVHD &gt; grade 2 or chronic GVHD manifestations: bronchiolitis obliterans
             syndrome, sclerotic GVHD, or serositis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine Bollard, MD</last_name>
    <phone>202-476-4776</phone>
    <email>cbollard@cnmc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fahmida Hoq, MBBS, MS</last_name>
    <phone>202-476-3634</phone>
    <email>fhoq@cnmc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kirsten Williams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shannon R. McCurdy, MD</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shannon McCurdy, MD</last_name>
      <email>smccurd2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Shannon McCurdy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 21, 2016</lastchanged_date>
  <firstreceived_date>July 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Research Institute</investigator_affiliation>
    <investigator_full_name>Catherine Bollard</investigator_full_name>
    <investigator_title>Director- CETI lab</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
